Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 3M | 1M | 609K | 112K | 0 |
| Gross Profit | 2M | 1M | 482K | 93K | 0 |
| Operating Income | -3M | -2M | -3M | -3M | -91K |
| EBITDA | -2M | -2M | -3M | -3M | 0 |
| Net Income | -3M | -2M | -3M | -3M | -91K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.9047
+0.00% today
1Y Change
-31.46%
Window
Jun 25, 2025 → Jun 23, 2026
Coverage: 252 bars · Jun 25, 2025 → Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Nuo Therapeutics, Inc. (AURX) is a Healthcare stock with a market cap of $60.00M. The stock last traded around $0.90 and down 31.5% across the available one-year price window (Jun 25, 2025 → Jun 23, 2026). Baseline metrics include revenue growth of +142.7%, EPS growth of -3.7%, a dividend yield of 0.0%. What stands out right now is revenue +142.7%, EPS -3.7%, free cash flow +52.2% with operating margin -76.0% and ROIC -408.7%. Valuation already assumes a fairly strong business story at price/sales 17.5. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines AURX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
AURX
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
AURX Max Drawdown
-71.99%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for AURX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
-100.0% YoY
FY Net Income
-$90.7K
+97.0% YoY
Free Cash Flow
-$13.0K
+99.7% YoY
Revenue Growth
+142.7%
EPS Growth
-3.7%
Gross Margin
66.9%
Net Margin
-75.8%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 3M | 1M | 609K | 112K | 0 |
| Gross Profit | 2M | 1M | 482K | 93K | 0 |
| Operating Income | -3M | -2M | -3M | -3M | -91K |
| EBITDA | -2M | -2M | -3M | -3M | 0 |
| Net Income | -3M | -2M | -3M | -3M | -91K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 549K | 284K | 929K | 2M | 148K |
| Total Assets | 2M | 1M | 2M | 3M | 150K |
| Total Liabilities | 3M | 676K | 839K | 856K | 672K |
| Shareholder Equity | -957K | 514K | 1M | 2M | -523K |
| Total Debt | 97K | 164K | 256K | 335K | 0 |
| Net Debt | -452K | -120K | -673K | -2M | -148K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
13K
+99.6% YoY
Capital Expenditures
0
+100.0% YoY
Free Cash Flow
13K
+99.7% YoY
Key ratios
Gross Margin
66.9%
Operating Margin
-76.0%
Net Margin
-75.8%
ROE
416.3%
Debt / Equity
-0.10x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.